Skip to content
HowShorted

Portola Pharmaceuticals, Inc. short interest in 2018

In 2018, Portola Pharmaceuticals, Inc.'s disclosed short interest ran from 6.83% of shares outstanding on 12 Jan 2018 to 24.03% on 31 Dec 2018, a change of +17.20 percentage points. The year's high was 25.42% on 15 Nov 2018 and its low 6.83% on 12 Jan 2018, averaging 15.67% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.35 days on 28 Sep 2018. Full history: Portola Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020

Aggregate net short position time series for Portola Pharmaceuticals, Inc. in 2018

2018 in figures

Start of year
6.83% (12 Jan 2018)
End of year
24.03% (31 Dec 2018)
Change
+17.20 pp
High
25.42% (15 Nov 2018)
Low
6.83% (12 Jan 2018)
Average
15.67%
Highest days to cover
16.35 (28 Sep 2018)
SEC filings marked
8

Every report in 2018

Portola Pharmaceuticals, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20186.83%4.83
31 Jan 20187.58%5.18
15 Feb 20187.69%5.92
28 Feb 20188.26%5.21results (8-K)
15 Mar 20188.05%2.0710-K filed
29 Mar 20188.16%4.19
13 Apr 20189.14%7.98
30 Apr 201810.57%7.14
15 May 201811.08%2.59results (8-K), 10-Q filed
31 May 201812.43%8.00
15 Jun 201812.88%6.80
29 Jun 201812.87%6.34
13 Jul 201812.64%14.06
31 Jul 201814.00%9.24
15 Aug 201816.46%4.6610-Q filed, results (8-K)
31 Aug 201822.13%8.00
14 Sep 201823.47%13.95
28 Sep 201824.23%16.35
15 Oct 201824.55%12.90
31 Oct 201823.38%9.97
15 Nov 201825.42%8.1810-Q filed, results (8-K)
30 Nov 201825.42%15.02
14 Dec 201824.72%9.66
31 Dec 201824.03%6.70

See also: Portola Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.